Systemic Mastocytosis

In this video, Lindsay A.M. Rein, MD, discussed the Summit trial into treatment of systemic mastocytosis, data from which was presented at the ASH Annual Meeting and Exposition.

The FDA approved avapritinib for treatment of adults with indolent systemic mastocytosis, according to a press release from the agent’s manufacturer.

The FDA approved avapritinib for treatment of adults with advanced systemic mastocytosis.

The FDA granted breakthrough therapy designation to avapritinib for treatment of moderate to severe indolent systemic mastocytosis, according to the agent’s manufacturer.